Patents Assigned to Pharmacyclics, Inc.
  • INHIBITORS OF BRUTON'S TYROSINE KINASE
    Publication number: 20110008257
    Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Application
    Filed: September 21, 2010
    Publication date: January 13, 2011
    Applicant: PHARMACYCLICS, INC.
    Inventors: Lee Honigberg, Erik Verner, Zhengying Pan
  • INHIBITORS OF BRUTON'S TYROSINE KINASE
    Publication number: 20100331350
    Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Application
    Filed: August 31, 2010
    Publication date: December 30, 2010
    Applicant: PHARMACYCLICS, INC.
    Inventors: Lee Honigberg, Erik Verner, Zhengying Pan
  • INHIBITORS OF BRUTON'S TYROSINE KINASE
    Publication number: 20100324050
    Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Application
    Filed: March 19, 2010
    Publication date: December 23, 2010
    Applicant: Pharmacyclics, Inc. A Delaware corporation
    Inventors: Lee HONIGBERG, Erik Verner, Zhengying Pan
  • MANUFACTURE, COMPOSITIONS AND USES OF COAGULATION FACTOR VIIa MODULATOR
    Publication number: 20100298396
    Abstract: Treatment of cancer and thromboembolic disorders using inhibitors of Factor VIIa are disclosed herein using a compound of Formula I.
    Type: Application
    Filed: October 16, 2008
    Publication date: November 25, 2010
    Applicant: PHARMACYCLICS, INC.
    Inventors: David Loury, Norbert Purro
  • Methods for determining cancer resistance to histone deacetylase inhibitors
    Patent number: 7838234
    Abstract: Described herein are methods and compositions for determining whether a particular cancer is resistant to or susceptible to a histone deacetylase inhibitor or to histone deacetylase inhibitors. The methods include analysis of the expression levels of at least four biomarker genes associated with response to a histone deacetylase inhibitor. Also described herein are methods and compositions for increasing the likelihood of a therapeutically effective treatment in a patient, comprising an analysis of the expression levels of at least four biomarker genes associated with response to a histone deacetylase inhibitor. Also described herein are isolated populations of nucleic acids derived from a cancer sensitive to or resistant to a histone deacetylase inhibitor. Further described are kits and indications that are optionally used in conjunction with the aforementioned methods and compositions.
    Type: Grant
    Filed: January 30, 2008
    Date of Patent: November 23, 2010
    Assignee: Pharmacyclics, Inc.
    Inventors: Joseph J. Buggy, Sriram Balasubramanian
  • Hydroxamates as therapeutic agents
    Patent number: 7834054
    Abstract: The present invention is directed to certain hydroxamate derivatives that are useful in the treatment of hepatitis C. These compounds are also inhibitors of histone deacetylase and are therefore useful in the treatment of diseases associated with histone deacetylase activity. Pharmaceutical compositions and processes for preparing these compounds are also disclosed.
    Type: Grant
    Filed: February 26, 2009
    Date of Patent: November 16, 2010
    Assignee: Pharmacyclics, Inc.
    Inventors: Erik J. Verner, Joseph J. Buggy
  • CALCIUM FLUX AS A PHARMACOEFFICACY BIOMARKER FOR INHIBITORS OF HISTONE DEACETYLASE
    Publication number: 20100285516
    Abstract: Described herein are methods for using calcium flux as a biomarker to select and predict patients likely to respond to an apoptotic agent as therapy. Further described herein is a method of using calcium flux as a clinical biomarker to determine whether a tumor is sensitive to an HDAC inhibitor.
    Type: Application
    Filed: April 11, 2008
    Publication date: November 11, 2010
    Applicant: PHARMACYCLICS, INC.
    Inventors: Sriram Balasubramanian, Joseph J. Buggy, Jason Ramos, Mint Sirisawad
  • Inhibitors of bruton's tyrosine kinase
    Patent number: 7825118
    Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Grant
    Filed: December 26, 2007
    Date of Patent: November 2, 2010
    Assignee: Pharmacyclics, Inc.
    Inventors: Lee Honigberg, Erik Verner, Zhengying Pan
  • Uses of selective inhibitors of HDAC8 for treatment of T-cell proliferative disorders
    Patent number: 7820711
    Abstract: Described herein are methods for treating a subject suffering from a T-cell lymphoma by administering to the subject a pharmaceutical composition containing a therapeutically effective amount of a selective inhibitor of histone deacetylase 8. Also described herein are methods for treating a subject suffering from a T-cell lymphoma by administering to the subject a population of autologous T-cells that have been exposed to a selective HDAC8 inhibitor composition ex vivo.
    Type: Grant
    Filed: July 18, 2007
    Date of Patent: October 26, 2010
    Assignee: Pharmacyclics Inc.
    Inventors: Joseph J. Buggy, Sriram Balasubramanian
  • Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
    Patent number: 7741330
    Abstract: Described herein are kinase inhibitor compounds, methods for synthesizing such inhibitors, and methods for using such inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate inhibitor of a protein, including a kinase.
    Type: Grant
    Filed: October 16, 2009
    Date of Patent: June 22, 2010
    Assignee: Pharmacyclics, Inc.
    Inventors: Wei Chen, David J. Loury, Tarak D. Mody
  • Inhibitors of Bruton's tyrosine kinase
    Patent number: 7732454
    Abstract: Disclosed herein are imidazo[1,5-f][1,2,4]triazine compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). The imidazo[1,5-f][1,2,4]triazine compounds described are irreversible inhibitors of Btk. Methods for the preparation of the imidazo[1,5-f][1,2,4]triazine compounds are disclosed. Also disclosed are pharmaceutical compositions that include the imidazo[1,5-f][1,2,4]triazine compounds. Methods of using the imidazo[1,5-f][1,2,4]triazine Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions; cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Grant
    Filed: March 28, 2007
    Date of Patent: June 8, 2010
    Assignee: Pharmacyclics, Inc.
    Inventor: Erik Verner
  • Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
    Patent number: 7718662
    Abstract: Described herein are kinase inhibitor compounds, methods for synthesizing such inhibitors, and methods for using such inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate inhibitor of a protein, including a kinase.
    Type: Grant
    Filed: October 16, 2009
    Date of Patent: May 18, 2010
    Assignee: Pharmacyclics, Inc.
    Inventors: Wei Chen, David J. Loury, Tarak D. Mody
  • HIGH-PURITY TEXAPHYRIN METAL COMPLEXES
    Publication number: 20100048916
    Abstract: Disclosed herein are the methods and compositions for the improved synthesis of texaphyrin metal complexes. The improved synthesis results in high-purity compositions of texaphyrin metal complexes in which more than about 98% of the texaphyrin metal complexes in the composition have the same structure and/or the same molecular weight. Further described herein are pharmaceutical compositions comprising such high-purity compositions, and the use of such high-purity compositions in the treatment of cancer and cardiovascular diseases and disorders.
    Type: Application
    Filed: November 3, 2009
    Publication date: February 25, 2010
    Applicant: PHARMACYCLICS, INC.
    Inventors: Hugo MADDEN, Greg HEMMI, Tarak MODY
  • INHIBITORS OF BRUTON'S TYROSINE KINASE
    Publication number: 20100041677
    Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Application
    Filed: July 7, 2009
    Publication date: February 18, 2010
    Applicant: PHARMACYCLICS, INC.
    Inventors: Lee HONIGBERG, Erik VERNER, Zhengying PAN
  • INHIBITORS OF TYROSINE KINASES AND USES THEREOF
    Publication number: 20100035841
    Abstract: Disclosed herein are compounds that inhibit the activity of particular tyrosine kinases. Methods for the preparation of such compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the compounds disclosed, alone or in combination with other therapeutic agents, for the treatment of tyrosine kinase-mediated diseases or conditions or tyrosine kinase-dependent diseases or conditions are provided.
    Type: Application
    Filed: October 7, 2009
    Publication date: February 11, 2010
    Applicant: Pharmacyclics, Inc.
    Inventors: Orion D. JANKOWSKI, James T. Palmer, Lee Honigberg
  • INHIBITORS OF BRUTON'S TYROSINE KINASE
    Publication number: 20100022561
    Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Application
    Filed: July 7, 2009
    Publication date: January 28, 2010
    Applicant: PHARMACYCLICS, INC.
    Inventors: Lee HONIGBERG, Erik VERNER, Zhengying PAN
  • INHIBITORS OF BRUTON'S TYROSINE KINASE
    Publication number: 20100004270
    Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Application
    Filed: July 7, 2009
    Publication date: January 7, 2010
    Applicant: Pharmacyclics, Inc.
    Inventors: Lee HONIGBERG, Erik VERNER, Zhengying PAN
  • Inhibitors of tyrosine kinases and uses thereof
    Patent number: 7625880
    Abstract: Disclosed herein are compounds that inhibit the activity of particular tyrosine kinases. Methods for the preparation of such compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the compounds disclosed, alone or in combination with other therapeutic agents, for the treatment of tyrosine kinase-mediated diseases or conditions or tyrosine kinase-dependent diseases or conditions are provided.
    Type: Grant
    Filed: December 28, 2006
    Date of Patent: December 1, 2009
    Assignee: Pharmacyclics, Inc.
    Inventors: Orion D. Jankowski, James T. Palmer, Lee Honigberg
  • Treatment of Non-Localized Inflammation with pan-HDAC Inhibitors
    Publication number: 20090270497
    Abstract: Described herein are compositions and methods for treating a subject suffering from a non-localized inflammatory condition (or any symptoms associated with such inflammation), including systemic inflammation, and inflammatory conditions affecting the large portions of or the whole body, or sepsis by administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of a compound that is a pan-HDAC inhibitor. Also described herein are methods for decreasing iNOS and cytokine expression by administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of a compound that is a pan-HDAC inhibitor.
    Type: Application
    Filed: April 24, 2009
    Publication date: October 29, 2009
    Applicant: PHARMACYCLICS, INC.
    Inventor: Joseph J. Buggy
  • NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS
    Publication number: 20090220454
    Abstract: The present invention is directed to certain hydroxamate derivatives that are useful in the treatment of hepatitis C. These compounds are also inhibitors of histone deacetylase and are therefore useful in the treatment of diseases associated with histone deacetylase activity. Pharmaceutical compositions and processes for preparing these compounds are also disclosed.
    Type: Application
    Filed: February 26, 2009
    Publication date: September 3, 2009
    Applicant: Pharmacyclics, Inc.
    Inventors: Erik J. Verner, Joseph J. Buggy